institutional data in comparison to Carolina breast cancer subtype, srvival study

1. Demographic pattern of incidence
of breast carcinoma by subtype
-A comparative study
Guvera vasireddy, Assistant professor
Dr. Triveni Bhopal, Professor
MNJ institute of Oncology / OMC
Dr. Ezhil Arasi. N, Professor and HOD
Department of pathology ,
Osmania Medical College, koti
Hyderabad, TelanganaState

4. Prevalence of Breast Cancer Subtypes According to Race and Menopausal Status in Carolina study
African American
Non African American
TumorSubtype
All cases
Pre menopausal
n = 97
Post menopausal
n = 99
Pre menopausal
n = 164
Post menopausal
n = 136
Triple negative
100
38(39)
14 (14)
26 (16)
22 (16)
Her2 positive
33
9 (9)
7 (7)
9 (6)
8 (6)
Luminal A
255
35 (36)
58 (59)
83 (51)
79 (58)
Luminal B
77
9 (9)
16 (16)
30 (18)
22 (16)
unclassified
31
6 (6)
4 (4)
16 (10)
5 (4)
figures in brackets are percentage

10. Therapy options
In different
molecular subtypes

18. IDCC with lymphocytic infiltration
Around the cell clusters.

19. Ernegativity
In the same case

20. Her2 3+ in plasma membrane

21. Estrogen receptor
Nuclear positivity

22. Progesterone positivity
In nuclei

23. ER negative
In nuclei

24. Estrogen receptor
Negativity
in nuclei of
the tumor cells
higher magnification

25. Her2 3+
Positive membrane
Staining in more than
10% of contiguous tumor cells

26. Her2 2+
Membrane positivity
In <10% of cells

27. Her2 1+
occasional
Membrane
positivity

29. Age Group
No.ofCases
Percentage
21-30
11
7
31-40
33
22
41-50
51
34
51-60
34
23
61 and Above
21
14

31. Age
Total
Total ER+ve
ER-ve
HER1+
HER2+
HER3+
HER- ve
HER1+
HER2+
HER3+
HER- ve
21-30
11
0
0
1
2
0
1
3
4
31-40
33
1
1
7
3
2
3
13
3
41-50
51
1
2
9
4
0
3
16
16
51-60
34
0
6
6
4
1
1
9
7
61 - above
21
0
3
4
4
0
3
1
6
Actual observation of receptor status

32. Her3+ 47%
Her2+ 21%
Her1+ 3%
Her Neg29%
Percentage of each category in ER+ve
ER+ve
58
Her3+
27
Her2+
12
Her1+
2
Her Neg
17

33. Her 3+ 46%
HER 2+ 12%
HER1+ 3%
HER -ve39%
Total Percentage in ER-ve
ER-ve Total
92
Her 3+
42
HER 2+
11
HER1+
3
HER -ve
36

34. Age Group
Total cases
Luminal A
LuminalB
Her2
Triple negative
HER2+
ER + ER -
21 -30
11
2
1
3
4
0
1
31 -40
33
4
7
13
5
1
3
41 -50
51
5
9
16
16
2
3
51 -60
34
4
6
9
8
6
1
61 and above
21
4
4
1
6
3
3
Total
150
19
27
42
39
12
11
Categorization in to subtypes according to age

35. Age Group
Total cases
Luminal A
LuminalB
Her2
Triple negative
unclassified
Pre menopausal
95
11 (11.57)
17 (17.89)
32 (33.68)
25 (26.31)
10 (9.5)
Postmenopausal
55
8 (14.54)
10(18.18)
10 (18.18)
14 (25.45)
13 (23.63)
Total
150
19 (12.66)
27 (18)
42 (28)
39 (26)
23 (15.33)
Categorization according to menopausal state

39. Studypopulation
African American population
Sub Types
Pre Menopausal
Post menopausal
Pre menopausal
Post menopausal
Triple Negative
25 (26.31)
14 (25.45)
38(39)
14 (14)
Her 2 Positive
32 (33.68)
10 (18.18)
9 (9)
7 (7)
Luminal A
11 (11.57)
8 (14.54)
35 (36)
58 (59)
Luminal B
17 (17.89)
10(18.18)
9 (9)
16 (16)
Unclassifiable
10 (9.5)
13 (23.63)
6 (6)
4 (4)
Total
95
55
97
99
Incidence of different subtypes in study population and African American population in CBS

41. Studypopulation
Non African Americans
Sub Types
Pre Menopausal
Post menopausal
Pre menopausal
n = 164
Post menopausal
n = 136
Triple Negative
25 (26.31)
14 (25.45)
26 (16)
22 (16)
Her 2 Positive
32 (33.68)
10 (18.18)
9 (6)
8 (6)
Luminal A
11 (11.57)
8 (14.54)
83 (51)
79 (58)
Luminal B
17 (17.89)
10(18.18)
30 (18)
22 (16)
Unclassifiable
10 (9.5)
13 (23.63)
16 (10)
5 (4)
Total
95
55
164
136
Incidence of different subtypes in study population and Non African American population in CBS

43. *Chandrika Rao, JayaprakashShetty, HL KishanPrasad
Department of Pathology, K S HegdeMedical Academy, Deralakatte, Mangalore, Karnataka, India

45. "The most important takeaway for our colleagues in breast cancer diagnosis and treatment is the potential value of molecular subtyping to personalize and improve each woman's treatment,"
Thank you all

47. Thankyouall